As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]
This is just one example, you can do the same
Between meals, the gallbladder is relaxed, but during meals, signals from the digestive tract stimulate contractions of the gallbladder and bile is released, through a system of ducts, into the intestine
A 2025 systematic review of spanning PubMed, Embase, and Cochrane found GLP-1 receptor agonists deliver HbA1c reductions of 1.52.0% in type 2 diabetes, 724% body weight loss in obesity treatment, and 1420% reduction in major adverse cardiovascular events (Emerging Frontiers in GLP-1 Therapeutics, PMC 2025)
Wegovy 2.4 mg weekly for weight management): Demonstrated 15-17% weight loss in STEP trials and significant cardiovascular benefits in SUSTAIN and SELECT trials Liraglutide (Victoza 1.8 mg daily for diabetes
PMID: 26236730 | doi:10.1155/2015/648108 Pickart L et al